Compare Travere Therapeutics Inc. Common Stock (TVTX) vs Weibo Corp (WB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Travere Therapeutics Inc. Common Stock vs Weibo Corp — how do they compare? Travere Therapeutics Inc. Common Stock trades at $52.74 (market cap $4.88B), while Weibo Corp trades at $6.43 (market cap $1.61B). The key difference: Travere Therapeutics Inc. Common Stock is far larger — about 3× Weibo Corp's market cap, and Weibo Corp pays a 9.3% dividend while Travere Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Travere Therapeutics Inc. Common Stock for 0 Days and Weibo Corp for 103 Days on average.
| TVTX | WB | |
|---|---|---|
Market Cap | $4.88B | $1.61B |
Volume | 1,668,577 | 585,008 |
Sector | Health | Media |
52-Week High | $67.52 | $11.52 |
52-Week Low | $26.79 | $6.33 |
Typical Hold Time | 0 Days | 103 Days |
Enterprise Value | $5.01B | $841.53M |
Dividend Yield | — | 9.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Weibo (WB) trades at $6.51, down 0.53% with bearish technical signals despite attractive valuation metrics including a P/E of 5.42 and P/B of 0.4. The company reported Q2 2026 EPS of $0.38, beating expectations, but faces declining user metrics and advertising revenue challenges. Cash flow trends show volatility with a significant net outflow in 2024 followed by recovery in 2025.
WB presents as a deep-value opportunity with strong profitability margins but faces growth headwinds from user engagement declines and competitive pressures. Analyst sentiment is mixed with 41% buy ratings versus 45% hold, reflecting uncertainty about the company's ability to maintain relevance in China's social media landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →About Weibo Corp
Weibo is the largest social media platform in China. As of 2020, Weibo had 521 million monthly active users and 225 million daily active users, many of whom are drawn there by the millions of key opinion leaders in entertainment, sports, and business circles. Sina is the major shareholder, holding 44.7% of shares and with 70.8% voting power.
Read more on WB →
